Table 4 Serious treatment-emergent AEs.

From: Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Preferred term, n (%)

Safety population (N = 39)

NCI CTCAE

Grade 1

Grade 2

Grade 3

Grade 4

Patients with ≥1 serious AE

7 (17.9)

0

1 (2.6)

5 (12.8)

2 (5.1)

 Gastroenteritis viral

1 (2.6)

0

0

1 (2.6)

0

 Parainfluenza virus infection

1 (2.6)

0

0

1 (2.6)

0

 Seizure

4 (10.3)

0

0

3 (7.7)

1 (2.6)

 Headache

1 (2.6)

0

1 (2.6)

0

0

 Hydrocephalus

1 (2.6)

0

0

1 (2.6)

0

 Hypertension

1 (2.6)

0

0

0

1 (2.6)

  1. Includes all serious AEs occurring on or after Day 1 of study treatment until 30 days after the last dose of study treatment. Multiple occurrences of AEs for a patient were counted only once at the highest NCI CTCAE grade.
  2. AEs adverse events, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events.